Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
8 evidence topics · 8 sources
Antigen-binding fragment that selectively inhibits C1q
Nonproprietary name description: anti-C1q globular head region Fab
Binding to the substrate-binding head groups of C1q
“ANX007 is a novel high affinity monoclonal antibody antigen-binding fragment (Fab) that was designed to specifically recognize the substrate-binding head groups of C1q to functionally inhibit the classical complement cascade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The blockade of C1q prevents recruitment and activation of all downstream components within the classical pathway, including C4, C3, and C5, that drive a local immune response and tissue destruction in the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Binding affinity and preservation of the lectin and alternative pathways
“ANX007 is an investigational, humanized antibody antigen-binding fragment that recognizes C1q and blocks its initiation of the classical complement pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By selectively targeting C1q, ANX007 inhibits the classical pathway while leaving the lectin and alternative complement pathways intact for normal immune function and tissue homeostasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ANX007 exhibits binding affinity for C1q (KD = 10 pM) and is a potent inhibitor of the classical complement cascade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product profile: 50 kD non-pegylated Fab with the anti-C1q structure of tanruprubart
“Modeled on established IVT Fab antibodies” (opens the source at this quote in a new tab)
“Same anti-C1q structure as tanruprubart” (opens the source at this quote in a new tab)
“Small 50 kD Fab antibody” (opens the source at this quote in a new tab)
“Full target engagement of classical pathway” (opens the source at this quote in a new tab)
Rationale for local C1q inhibition in geographic atrophy
Proposed differences from C3 and C5 inhibition
“However, C3 and C5 inhibitors block the central and terminal aspects of all three complement pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, preventing the focused binding of C1q to its substrates would block all downstream classical cascade components and their amplification to reduce overall complement activation, while leaving the clearance and tissue repair functions of the lectin and alternative complement pathways in place.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote